BioSyent Declares First Quarter 2024 Dividend
February 06 2024 - 4:30PM
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is
pleased to announce that its Board of Directors has declared a
quarterly dividend of $0.045 per common share, payable in Canadian
Dollars on March 15, 2024, to shareholders of record at the close
of business on February 29, 2024. This first quarter 2024 dividend
of $0.045 per common share represents a 12.5% increase from the
fourth quarter 2023 dividend of $0.040 per common share. This
dividend qualifies as an 'eligible dividend' for Canadian income
tax purposes. The declaration, timing, amount and payment of future
dividends remain at the discretion of the Board of Directors.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the
trading symbol “RX”, BioSyent is a profitable growth-oriented
specialty pharmaceutical company focused on in-licensing or
acquiring innovative pharmaceutical and other healthcare products
that have been successfully developed, are safe and effective, and
have a proven track record of improving the lives of patients.
BioSyent supports the healthcare professionals that treat these
patients by marketing its products through its community, specialty
and international business units.
As of the date of this press release, the
Company has 11,674,679 common shares outstanding.
For a direct market quote for the TSX Venture
Exchange and other Company financial information please visit
www.tmxmoney.com.
For further information please
contact:Mr. René C. GoehrumPresident and CEOBioSyent
Inc.E-Mail: investors@biosyent.comPhone: 905-206-0013Web:
www.biosyent.com
This press release may contain information or
statements that are forward-looking. The contents herein represent
our judgment, as at the release date, and are subject to risks and
uncertainties that may cause actual results or outcomes to be
materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to,
those associated with clinical trials, product development, future
revenue, operations, profitability and obtaining regulatory
approvals.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this press release.
Biosyent (TSXV:RX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Biosyent (TSXV:RX)
Historical Stock Chart
From Aug 2023 to Aug 2024